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Abstract: Background: Primary and secondary myelofibrosis (PMF; SMF) are malignant diseases of the 
hematopoietic stem-cell characterized by the neoplastic myeloproliferation and strong inflammatory milieu. 
Prognostic-Nutritional-Index (PNI) integrates information on albumin and absolute-lymphocyte-count (ALC) and 
reflects inflammatory, nutritional and immune status of a patient. Clinical and prognostic significance of albumin, 
ALC and PNI in patients with myelofibrosis have not been previously investigated.   
Methods: We retrospectively analyzed a cohort of 83 myelofibrosis patients treated in our institution from 2006 
to 2017. Albumin, ALC and PNI were assessed in addition to other disease-specific markers.   
Results: PMF and SMF patients had significantly lower ALC and PNI and similar albumin compared to controls. 
Lower albumin was significantly associated with older age and parameters reflecting more aggressive disease 
biology (anemia, lower platelets, higher LDH, circulatory-blasts, transfusion-dependency, blast-phase-disease), 
inflammation (higher CRP, constitutional-symptoms) and higher degree of bone-marrow-fibrosis. Lower ALC 
was significantly associated with lower white-blood-cells (WBC) and lower circulatory-blasts. Low PNI was 
associated with lower albumin, lower ALC, anemia, lower WBCs, lower serum-iron and lower transferrin-
saturation. There was no difference in albumin, ALC and PNI regarding the driver-mutations. In multivariate 
analysis adjusted for age and gender, low-albumin (HR=4.61, P=0.001), low-ALC (HR=3.54, P=0.004) and 
DIPSS (HR=2.45, P=0.001) were able to predict inferior survival independently of each other. Accordingly, low-
PNI (HR=4.32, P<0.001) predicted poor survival independently of DIPSS (HR=3.31, P<0.001).  
Conclusion: Assessing albumin, ALC and PNI might improve prognostication in patients with myelofibrosis and 
could assist in recognition of patients under increased risk of death.  
 
Keywords: Philadelphia chromosome negative myeloproliferative neoplasm; Primary myelofibrosis; Secondary 
myelofibrosis; Survival; Nutrition 
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Introduction: 
Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms (MPN) [1] are clonal disorders of the 
hematopoietic stem cell. Most patients carry a mutation in either of Janus-kinase-2 (JAK2), calreticulin (CALR) 
or myeloproliferative-leukemia-virus-oncogene (MPL) genes [2] resulting in a constitutive activation of 
JAK/signal-transducer-and-activator-of-transcription (STAT) signaling pathway and a highly inflammatory 
milieu typical for these diseases [3]. Primary myelofibrosis (PMF) exhibits the most aggressive biological 
behavior among the Ph- MPNs and bears the highest risk of transformation to acute leukemia and death [4, 5]. It 
is characterized by megakaryocytic proliferation and atypia, progressive bone marrow fibrosis, 
leukoerythroblastic blood smear and development of hepatosplenomegaly due to induction of extramedullary 
hematopoiesis. Patients often suffer from debilitating constitutional symptoms and develop varying number and 
degree of myeloid lineage cytopenias. Patients with two other Ph- MPNs ‒ polycythemia rubra vera (PRV) and 
essential thrombocythemia (ET) ‒ can also develop bone marrow fibrosis and PMF-related features during their 
disease course [6], when these conditions are termed secondary myelofibrosis (SMF).  
PMF and SMF patients have similar clinical presentation and experience similar clinical course. The risk of death 
in myelofibrosis patients can be determined using the International Prognostic Scoring System (IPSS) [7] at the 
time of diagnosis and the Dynamic International Prognostic Scoring System (DIPSS) [8] during the course of the 
disease. Both prognostic systems assign scores for the patient’s age, white blood cell (WBC) count, hemoglobin 
level, presence of circulatory blasts and the presence of constitutional symptoms. 
Serum albumin concentration and absolute lymphocyte count (ALC) are traditional measures of nutritional status 
that are also influenced by other non-nutritional factors, such as inflammation, stress and specific illness [9-15]. 
The Prognostic Nutritional Index (PNI), as proposed by Onodera et al. [16], integrates information on these two 
parameters and is calculated as PNI = serum albumin (g/L) + [5 × ALC (×109/L)]. This simple indirect measure 
of immunocompetence, inflammatory and nutritional status has been shown to be predictive of overall survival 
and perioperative complications in various malignancies [17-22].   
A subset of myelofibrosis patients presents with a significant weight loss and cachexia which represents an 
important clinical problem [23]. Similarly, a majority of myelofibrosis patients presents with a lymphocytopenia 
and a disturbance in lymphocyte subsets [24]. However, potential prognostic implications of low serum albumin, 
low ALC and PNI have not been previously studied in patients with myelofibrosis.  
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In this study, we aim to investigate clinical associations of serum albumin concentration, ALC and PNI in patients 
with myelofibrosis and assess potential prognostic significance of these parameters. 
 
Patients, Materials and Methods: 
Patients 
A total of 83 patients with myelofibrosis that were treated in our department in the period from 2006 to 2017 were 
retrospectively analyzed. All patients fulfilled the World Health Organization (WHO) 2016 criteria for the 
diagnosis of PMF [1] and the International Working Group for Myelofibrosis Research and Treatment (IWG-
MRT) criteria for the diagnosis of SMF [6]. A total of 69 (83.1%) patients were evaluated at the time of 
establishing diagnosis and 14 (16.9%) patients were evaluated at the time of referral to our institution. All patients 
provided a written informed consent for the molecular analyses. The study was approved by the Institutional 
Review Board. All procedures were in accordance with the ethical standards of the responsible committee on 
human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. 
Degree of bone marrow fibrosis was determined according to the current European consensus [25]. Serum albumin 
concentration and ALC were recorded in addition to other demographic, hematological and clinical parameters 
(age, gender, WBC count, circulatory blasts, hemoglobin level, mean corpuscular volume (MCV), red cell 
distribution width (RDW), platelet count, C reactive protein (CRP) level, lactate dehydrogenase (LDH) level, 
serum iron level, total iron binding capacity (TIBC), transferrin saturation, ferritin level, presence of constitutional 
symptoms, blast phase disease, transfusion dependency, JAK2, CALR and MPL mutational status). Disease was 
staged according to the DIPSS, spleen and liver size were assessed by palpation. PNI was calculated as serum 
albumin (g/L) + [5 × ALC (×109/L)]. Additionally, albumin, ALC and PNI of PMF and SMF patients were 
compared to 30 age and gender matched healthy controls. 
 
Molecular analyses 
DNA was isolated from full blood by QIAamp DNA Blood Mini Kit (Qiagen, ID 51104). JAK2 V617F was 
assessed by allele-specific PCR as described previously [26], CALR1 and MPL exon 10 mutations were screened 
by high–resolution melting dye assays [27, 28] and any sample sequence that deviated from normal was Sanger 
sequenced.  
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Statistical analyses 
The normality of data distribution was tested using the Kolmogorov-Smirnov test. Numerical variables were 
presented as either median with interquartile range (IQR), or as arithmetic mean ± standard deviation depending 
on the normality of distribution. Categorical variables were presented as proportions. The Mann Whitney U 
test/the T-test, the Kruskal-Wallis test, the χ2 (Chi squared) test and the Spearman rank correlation were utilized 
where appropriate. The Jonckheere-Terpstra test for trend was used to test trends of increase in numerical values 
over DIPSS risk categories. Survival analyses [29] were performed using the methods of Kaplan and Meier, the 
Cox-Mantel version of the log-rank test [30] and the Cox regression analysis. Receiver operating characteristic 
(ROC) curve analysis using survival status as a classification variable was performed in order to determine optimal 
cut-off values for survival analyses. P values <0.05 were considered significant. Associations of different 
prognostic factors with survival were screened for via a custom made MS Excel workbook [31]. Analyses were 
performed using MedCalc Statistical Software version 17.6 (MedCalc Software BVBA, Ostend, Belgium). 
 
Results: 
Overview of myelofibrosis patients 
In our study, we analyzed a total of 83 patients with myelofibrosis, 63 (75.3%) of whom were diagnosed with 
PMF and 20 (24.7%) with SMF. Mean patient age was 65.6 ± 10.4 years, with 51/83 (61.4%) patients of male 
gender. Patients’ characteristics are listed in Table 1. 
Median follow up of our cohort of patients was 51 months. Median overall survival was 67 months and it did not 
differ between PMF and SMF patients. 
 
Serum albumin concentration 
Median serum albumin concentration was 44 g/L, IQR (40 - 46) and it did not significantly differ between PMF, 
SMF and controls (P=0.865) as shown in Figure 1A. Only a small subset of patients, 7/83 (8.4%), presented with 
hypoalbuminemia, defined as a serum albumin level lower than 35 g/L.  
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Higher serum albumin concentration was significantly associated with younger age (Rho= -0.25, P=0.026), higher 
hemoglobin level (Rho=0.41, P<0.001), lower percentage of circulatory blasts (Rho= -0.33, P=0.002), higher 
platelet count (Rho=0.26, P=0.021), lower LDH level (Rho= -0.39, P<0.001), lower RDW (Rho=-0.37, P=0.001), 
lower CRP level (Rho= -0.5, P<0.001), higher serum iron level (Rho=0.38, P=0.003), higher TIBC (Rho=0.28, 
P=0.029), absence of constitutional symptoms (median 42 g/L vs 44.5 g/L for patients with and without 
constitutional symptoms, P=0.001), absence of blast phase disease (median 35 g/L vs 44 g/L for patients with and 
without leukemic transformation of myelofibrosis, P<0.001), transfusion independency (median 40 g/L vs 44 g/L 
for transfusion dependent and transfusion independent patients, P=0.019) and lower degree of bone marrow 
fibrosis (Rho= -0.25, P=0.035) as depicted in Figure 2A. There was a clear and significant trend of decrease in 
serum albumin values over DIPSS risk categories (P<0.001) as shown in Figure 2B. There was no statistically 
significant correlation between serum albumin concentration and gender, WBC count, ALC, spleen and liver size, 
MCV, transferrin saturation, ferritin level, JAK2, CALR or MPL mutational status. 
Optimal serum albumin cut-off value for survival analyses was determined using the ROC curve analysis and 
patients were divided into High albumin (>42 g/L) and Low albumin (≤42 g/L) groups. Low albumin was 
univariately associated with shorter overall survival (HR=6.49, P<0.001) as shown in Figure 3A. This association 
remained significant in the Cox regression model adjusted for age, gender and DIPSS (Low albumin HR=3.84, 
P<0.001; DIPSS HR=2.51, P<0.001; age and gender not significant).  
 
Absolute lymphocyte count 
Median ALC was 1.5 ×109/L, IQR (1 - 1.9) and it differed significantly between patients and controls (P<0.001). 
Although there was no significant difference between PMF and SMF patients in regard to ALC, both subgroups 
had significantly lower values in comparison to controls (P<0.05 for both comparisons) as depicted in Figure 1B. 
A subset of 16/83 (19.3%) patients presented with ALC values lower than 1 ×109/L. 
Higher ALC was significantly associated with higher WBC count (Rho=0.48, P<0.001) and higher percentage of 
circulatory blasts (Rho=0.28, P=0.010). We did not observe statistically significant correlation with other tested 
parameters (age, gender, hemoglobin level, platelet count, LDH level, CRP level, albumin, MCV, RDW, 
parameters of iron metabolism, spleen or liver size, constitutional symptoms, transfusion dependency, blast phase 
disease, degree of bone marrow fibrosis, JAK2, CALR or MPL mutational status). In addition, ALC did not 
correlate with DIPSS. 
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Optimal ALC cut-off value for survival analyses was determined by the ROC curve analysis and patients were 
divided into High ALC (>0.86 ×109/L) and Low ALC (≤0.86 ×109/L) groups. Low ALC group presented with 
significantly shorter overall survival (HR=2.86, P=0.005) as shown in Figure 3B. Low ALC remained 
significantly associated with poor survival in the multivariate Cox regression model adjusted for age, gender and 
DIPSS (Low ALC HR=3.65, P=0.002; DIPSS HR=3.66, P<0.001; age and gender not significant). We could also 
demonstrate that Low ALC, Low albumin and DIPSS can predict inferior overall survival independently of each 
other in the model including Low ALC, Low albumin and DIPSS, age and male gender as specified in Table 2. 
 
Prognostic Nutritional index (PNI) 
We further investigated how PNI, which incorporates information on serum albumin concentration and absolute 
lymphocyte count, affects survival of patients with myelofibrosis. Median PNI was 50.5, IQR (47 - 55.5) and it 
did not statistically significantly differ between PMF and SMF patients, but was lower in both groups of patients 
when compared to healthy controls (P<0.05 for both comparisons). Patients were divided into subgroups based 
on the PNI score quartiles and we could demonstrate that there is a significant difference in overall survival 
between patient groups (P<0.001) as shown in Figure 3C. Patients with PNI lower than the first quartile (PNI <47) 
had significantly inferior overall survival in comparison to all the other subgroups (P<0.008 for all comparisons, 
considering the Bonferroni correction for multiple comparisons). Patients in other three subgroups based on PNI 
quartiles had similar disease course and did not significantly differ in overall survival. Having PNI <47 remained 
statistically significantly associated with shorter overall survival in the Cox regression model adjusted for age, 
gender and DIPSS (PNI <47 HR=4.32, P<0.001; DIPSS HR=3.31, P<0.001; age and gender not significant). 
Patients with the PNI lower than the first quartile expectedly had lower serum albumin concentration (median 
38.5 g/L vs 45 g/L, P<0.001) and lower ALC (median 0.93 x109/L vs 1.5 x109/L, P<0.001), but also had lower 
hemoglobin level (100.5 ±16.7 vs 117.1 ±26.8 g/L, P=0.018), lower WBC count (median 6.9 vs 11.4 x109/L, 
P=0.044), lower serum iron level (median 5.3 vs 13.2, P=0.006) and lower transferrin saturation (median 8% vs 
27%, P=0.020) compared to those with the higher PNI, but did not significantly differ in other disease-specific 
parameters.  
 
Discussion:  
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To the best of our knowledge, this study is first to investigate clinical correlations and prognostic significance of 
serum albumin, ALC and PNI in patients with myelofibrosis and to report their DIPSS-independent prognostic 
properties. 
Although being traditionally considered as measures of nutritional status [9-12], serum albumin concentration and 
ALC are strongly affected by a variety of other factors, most notably inflammation [13, 32]. As we have shown 
in our current study, lower serum albumin level was associated with parameters reflecting more aggressive disease 
biology (higher LDH level, higher percentage of circulatory blasts, blast phase disease, transfusion dependency), 
higher inflammatory milieu (higher CRP level, presence of constitutional symptoms) and also with parameters 
that could reflect nutritional status of PMF/SMF patients (lower serum iron level, anemia). Lower serum albumin 
was associated with an increasing degree of bone marrow fibrosis suggesting that these two phenomena might be 
regulated by a similar cytokine profile. Associations of low serum albumin with a large number of aforementioned 
negative prognostic parameters were reflected in inferior overall survival in our cohort of patients. Treatment of 
myelofibrosis patients with JAK1/2 inhibitor ruxolitinib typically results in a reduction of inflammatory cytokines, 
improvement of constitutional symptoms and a reduction in spleen size, but also in an improvement in body 
weight and serum albumin concentration [33]. Survival advantage seen in a subset of ruxolitinib-treated patients 
might be at least in part mediated through the improvement in nutritional status. However, role of albumin as 
prognostic marker in this setting has not yet been evaluated.  
Our finding of a decreased ALC in myelofibrosis patients in comparison to healthy controls is in line with the 
previous observation of lymphocytopenia as a characteristic feature of the disease [24]. Remarkably, ALC did not 
show statistically significant associations with most parameters of disease severity, except positive correlations 
with WBC count and circulatory blasts which are considered to be negative prognostic markers [7]. Quite 
oppositely, higher ALC in our cohort of patients seems to bear positive prognostic implications, and its effect on 
improved survival could be mediated by decreased susceptibility to infections as observed in other clinical 
situations [34]. Recent large retrospective study that investigated factors associated with infections in patients 
with myelofibrosis unfortunately did not investigate lymphocyte count as a possible factor [35], leaving this issue 
unresolved. In addition, neither serum albumin, nor ALC were associated with mutations in JAK2, CALR and 
MPL genes suggesting that their changes do not reflect driver mutation-specific phenomena.  
Our most striking observation was that low serum albumin, low ALC and DIPSS all seem to provide additional 
prognostic information and could predict inferior overall survival independently of each other (Table 2). This 
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suggests that all three parameters reflect different pathophysiological processes and assessing all three of them 
might improve prognostication of patients with myelofibrosis. Due to their independent associations with survival 
in these patients, it is reasonable to combine information on serum albumin and ALC into a composite index 
abbreviated PNI as previously proposed by Onodera et al. [16]. PNI is considered to reflect inflammatory, 
nutritional and immune status of an oncological patient and was shown to be of prognostic value in a variety of 
malignant neoplastic diseases [17-22]. As we have observed in our cohort of myelofibrosis patients, a quarter of 
patients presenting with the lowest PNI values (<47) had lower WBC count, lower hemoglobin level, lower serum 
iron level and lower transferrin saturation in addition to lower serum albumin concentration and lower ALC which 
all might have been affected by the nutritional status of a patient. A quarter of patients presenting with the lowest 
PNI values experienced unfavorable disease course with the significantly shorter overall survival in comparison 
to other three sub-cohorts (Figure 3C). Interestingly, all patients with PNI ≥47 had similar prognosis and their 
survival was not significantly affected by the assignment to the particular PNI subgroup. Therefore, only reaching 
below critical PNI threshold seems to be negatively affecting survival through a process that might be independent 
of disease-specific mechanisms measured by the currently established DIPSS prognostic system. 
Main limitations of our work are single institution experience, retrospective study design, small number of patients 
and heterogenous patient population. Retrospective study design prevents us from assessing anthropometric 
measures of nutritional status such as body mass index, waist circumference or triceps skin fold, as well as 
correlating them to parameters of interest. In addition, study was conducted over an 11-year period during which 
patients were exposed to different disease-oriented and other supportive therapies that might modulate effects of 
measured parameters. A subset of patients that were treated upfront with ruxolitinib (at the time of diagnosis) was 
relatively small and most of intermediate-2 and high risk patients received the drug later during course of their 
disease (when it became available), and not synchronous with the study baseline. Short follow up / small number 
of events and consequent statistical power limitations prevent us from properly investigating whether studied 
phenomena persist in a subcohort of ruxolitinib treated patients. Nevertheless, our study identifies serum albumin, 
ALC and PNI as useful and easy-to-obtain parameters that bear valuable clinical information in patients with 
myelofibrosis. Hence, future studies investigating these parameters in larger prospective cohorts of patients are 
warranted, especially from the point of view of new and emerging therapies with “cachexia modulatory” 
properties.  
In conclusion, serum albumin, ALC and DIPSS predict survival independently of each other. PNI integrates 
information on serum albumin and ALC and similarly provides DIPSS-independent prognostic information. 
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Assessing these parameters could improve prognostication of patients with myelofibrosis and help in recognition 
of patients under the increased risk of death, therefore enabling timely supportive interventions. 
 
Ethical approval: The study was approved by the Institutional Review Board. 
Conflict of interest: All authors report no conflicts of interest. 
Informed consent:  All subjects in whom molecular studies were performed provided written informed consent. 
Funding: none 
 
References: 
1. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification 
of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. 
2. Sliwa T, Beham-Schmid C, Burgstaller S et al. Austrian recommendations for the management of 
primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: 
an expert statement. Wien Klin Wochenschr. 2017;129(9-10):293-302. 
3. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia 
vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of 
accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219-25. 
4. Hultcrantz M, Kristinsson SY, Andersson TM et al. Patterns of survival among patients with 
myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 
2012;30(24):2995-3001. 
5. Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature 
Review on Risk, Characteristics, and Outcome. Mayo Clin Proc. 2017;92(7):1118-28. 
6. Barosi G, Mesa RA, Thiele J et al. Proposed criteria for the diagnosis of post-polycythemia vera and 
post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for 
Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-8. 
7. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based 
on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 
2009;113(13):2895-901. 
11 
 
8. Passamonti F, Cervantes F, Vannucchi AM et al. A dynamic prognostic model to predict survival in 
primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative 
Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8. 
9. Tayek JA. Albumin synthesis and nutritional assessment. Nutr Clin Pract. 1988;3(6):219-21. 
10. Fock RA, Blatt SL, Beutler B et al. Study of lymphocyte subpopulations in bone marrow in a model of 
protein-energy malnutrition. Nutrition. 2010;26(10):1021-8. 
11. Rocha NP, Fortes RC. Total lymphocyte count and serum albumin as predictors of nutritional risk in 
surgical patients. Arquivos Brasileiros de Cirurgia Digestiva : ABCD = Brazilian Archives of Digestive Surgery. 
2015;28(3):193-6. 
12. Saito H, Nomura K, Hotta M, Takano K. Malnutrition induces dissociated changes in lymphocyte count 
and subset proportion in patients with anorexia nervosa. Int J Eat Disord. 2007;40(6):575-9. 
13. Bharadwaj S, Ginoya S, Tandon P et al. Malnutrition: laboratory markers vs nutritional assessment. 
Gastroenterol Rep (Oxf). 2016;4(4):272-80. 
14. Zhang Z, Pereira SL, Luo M, Matheson EM. Evaluation of Blood Biomarkers Associated with Risk of 
Malnutrition in Older Adults: A Systematic Review and Meta-Analysis. Nutrients. 2017;9(8). 
15. Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment 
of the hospitalized patient. JPEN J Parenter Enteral Nutr. 1977;1(1):11-22. 
16. Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished 
cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001-5. 
17. Perisa V, Zibar L, Knezovic A, Perisa I, Sincic-Petricevic J, Aurer I. Prognostic nutritional index as a 
predictor of prognosis in patients with diffuse large B cell lymphoma. Wien Klin Wochenschr. 2017;129(11-
12):411-9. 
18. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in 
cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537-49. 
19. Okada S, Shimada J, Kato D, Tsunezuka H, Teramukai S, Inoue M. Clinical Significance of Prognostic 
Nutritional Index After Surgical Treatment in Lung Cancer. Ann Thorac Surg. 2017;104(1):296-302. 
20. Yang Y, Gao P, Chen X et al. Prognostic significance of preoperative prognostic nutritional index in 
colorectal cancer: results from a retrospective cohort study and a meta-analysis. Oncotarget. 2016;7(36):58543-
52. 
12 
 
21. Lee JY, Kim HI, Kim YN et al. Clinical Significance of the Prognostic Nutritional Index for Predicting 
Short- and Long-Term Surgical Outcomes After Gastrectomy: A Retrospective Analysis of 7781 Gastric Cancer 
Patients. Medicine (Baltimore). 2016;95(18):e3539. 
22. Lee SH, Chung MJ, Kim B et al. The Significance of the Prognostic Nutritional Index for All Stages of 
Pancreatic Cancer. Nutr Cancer. 2017;69(3):512-9. 
23. Scherber RM, Mesa RA. Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the 
Treatment of Myeloproliferative Neoplasms— Implications for a JAK2 Inhibitor Era. Oncol Hematol Rev. 
2011;7(1):61-3. 
24. Cervantes F, Hernandez-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood 
lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000;65(2):104-8. 
25. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading 
bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-32. 
26. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human 
myeloproliferative disorders. Lancet. 2005;365(9464):1054-61. 
27. Bilbao-Sieyro C, Santana G, Moreno M et al. High resolution melting analysis: a rapid and accurate 
method to detect CALR mutations. PLoS One. 2014;9(7):e103511. 
28. Pardanani A, Guglielmelli P, Lasho TL et al. Primary myelofibrosis with or without mutant MPL: 
comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25(12):1834-9. 
29. Lucijanic M, Petrovecki M. Analysis of censored data. Biochem Med (Zagreb). 2012;22(2):151-5. 
30. Lucijanic M, Skelin M, Lucijanic T. Survival analysis, more than meets the eye. Biochem Med. 
2017;27(1):14–8. 
31. Lucijanic M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. 
Croat Med J. 2016;57(1):77-9. 
32. Nunez J, Minana G, Bodi V et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 
2011;18(21):3226-33. 
33. Mesa RA, Verstovsek S, Gupta V et al. Effects of Ruxolitinib Treatment on Metabolic and Nutritional 
Parameters in Patients With Myelofibrosis From COMFORT-I. Clinical lymphoma, myeloma & leukemia. 
2015;15(4):214-21.e1. 
34. Gluck T, Kiefmann B, Grohmann M, Falk W, Straub RH, Scholmerich J. Immune status and risk for 
infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005;32(8):1473-80. 
13 
 
35. Polverelli N, Breccia M, Benevolo G et al. Risk factors for infections in myelofibrosis: role of disease 
status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92(1):37-41. 
 
 
  
14 
 
Table 1: Patients’ characteristics. Abbreviations: PMF – primary myelofibrosis; SMF – secondary myelofibrosis; 
JAK2 – Janus kinase 2; CALR – calreticulin; MPL – myeloproliferative leukemia virus oncogene; WBC – white 
blood cells; IQR – interquartile range; RDW – red cell distribution width; LDH – lactate dehydrogenase; CRP – 
C reactive protein, ALC – absolute lymphocyte count, PNI – Prognostic Nutritional Index.   
Number of patients 83 
Diagnosis PMF 63/83 (75.9%) 
SMF 20/83 (24.1%) 
Age (years) 65.6 ±10.4 
Gender Male 51/83 (61.4%) 
Female 32/83 (38.6%) 
Bone marrow fibrosis Grade 0-I 33/83 (39.8%) 
Grade II-III 50/83 (60.2%) 
JAK2 mutated 52/80 (65%) 
CALR mutated 8/63 (12.7%) 
MPL mutated 2/63 (3.2%) 
Constitutional symptoms 30/82 (36.6%) 
Massive splenomegaly 19/80 (23.8%) 
Blast phase disease 8/83 (9.6%) 
WBC (x109/L) 11 IQR (6.9 - 17.4) 
>1% circulatory blasts 30/82 (36.6%) 
Hemoglobin level (g/L) 113.6 ±25.9 
Platelets (x109/L) 336 IQR (178 - 574) 
RDW (%) 19.6 IQR (18.1 - 21.1) 
LDH (U/L) 539 IQR (326 - 766.5) 
CRP (mg/L) 5.3 IQR (2 - 15.1) 
Albumin (g/L) 44 IQR (40 - 46) 
ALC (x109/L) 1.5 IQR (1 - 1.9) 
PNI 50.5 IQR (47 - 55.5) 
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Table 2: Age and gender adjusted Cox regression analysis model demonstrating independent prognostic 
properties of low albumin, low absolute lymphocyte count (ALC), and Dynamic International Prognostic Scoring 
System (DIPSS) in patients with myelofibrosis. Abbreviations: HR – hazard ratio, C.I. – confidence interval. 
Variable HR 95% C.I. for HR P value 
Low albumin 4.61 [1.96 - 10.85] 0.001* 
Low ALC 3.54 [1.5 - 8.37] 0.004* 
DIPSS 2.45 [1.42 - 4.22] 0.001* 
Age 1.02 [0.98 - 1.07] 0.338 
Male gender 0.79 [0.36 - 1.71] 0.548 
* statistically significant result (P<0.05) 
 
  
16 
 
Figure 1: A) There was no statistically significant difference in serum albumin concentration between patients 
with primary myelofibrosis (PMF), secondary myelofibrosis (SMF) and healthy controls. B) Patients with PMF 
and SMF had significantly lower absolute lymphocyte count (ALC) in comparison to controls, whereas there was 
no statistically significant difference between PMF and SMF.    
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Figure 2: A) Serum albumin was negatively correlated with the degree of bone marrow fibrosis. B) Serum 
albumin showed a significant trend of decrease with a higher Dynamic International Prognostic Scoring System 
(DIPSS) risk category. Abbreviations: Int. – intermediate.   
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Figure 3: Overall survival (OS) of patients with myelofibrosis stratified by A) serum albumin concentration, B) 
absolute lymphocyte count (ALC) and C) Prognostic Nutritional Index (PNI). Abbreviations: HR – hazard ratio, 
qrt. – quartile. 
 
